Protein Design announces agreement with Celltech Chiroscience for antibody patents.
Each company will pay royalties to the other on potential sales of licensed antibodies.
" Protein Design has a strong intellectual property position in the antibody field, with issued patents in the United States, Europe and Japan that we believe cover most humanized antibodies," said Robert L. Kirkman, MD, vice president, business development and corporate communications. "Celltech is the twenty-sixth company to enter into a patent agreement with Protein Design under the Queen et. al. patents."
Protein Design has granted licenses and other rights under its antibody humanization patents to pharmaceutical and biotechnology companies worldwide covering more than 35 humanized antibodies, more than half of which are currently in clinical development and three of which are marketed. Protein Design currently receives royalties from sales of: Synagis (palivizumab), for the prevention of respiratory syncytial virus disease in infants, developed by MedImmune, Inc. (Gaithersburg, MD; 301-417-0770); Herceptin (trastuzumab), for the treatment of breast cancer, developed by Genentech, Inc. (S. San Francisco, CA; 415-266-1000); and Zenapax (daclizumab), an antibody created by Protein Design and licensed to Hoffmann-La Roche, Inc. (Nutley, NJ), which is marketed for the prevention of acute kidney transplant rejection.
Protein Design is a leader in the development of humanized antibodies to prevent or treat various disease conditions. Protein Design currently has antibodies under development for autoimmune and inflammatory conditions, transplantation and cancer. Protein Design holds fundamental patents in the United States, Europe and Japan for its antibody humanization technology.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Protein Design Labs, Inc.|
|Comment:||Protein Design announces agreement with Celltech Chiroscience for antibody patents.(Protein Design Labs, Inc.)|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Jan 1, 2000|
|Previous Article:||Targeted Genetics licenses key gene expression technology to GTI/Systemix.|
|Next Article:||Thm Biomedical receives patent for a method and device for the reconstruction of articular cartilage.|